TP53 and malignant colon neoplasm: For this purpose, we used HCT116 isogenic colon cancer cells differing in p53 status: we introduced p53 mutations, which frequently observed in malignant tumors, into p53-negative HCT116 cells and treated these p53-mutant cells with liquid plasma.